The Lonza Board of Directors announced the nomination of Stephen Fry as an Independent Member of the Board, with his election scheduled for the Lonza Group Annual General Meeting in May 2026. Subject to approval, Fry will also join both the People and Governance Committee and the Audit and Compliance Committee, bringing pharmaceutical industry expertise and organizational leadership experience to the Swiss contract development and manufacturing organization.
Fry's nomination carries significance for Lonza's strategic direction as the company navigates the competitive healthcare manufacturing landscape. With over three decades at Eli Lilly and Company, where he ultimately served as Executive Vice President and Chief Human Resources Officer for twelve years, Fry developed expertise in large-scale organizational transformation, high-performance culture development, and executive leadership during periods of significant industry change. His background complements Lonza's existing board capabilities at a time when talent retention and organizational agility are critical for CDMOs serving pharmaceutical and biotech innovators.
"Stephen brings extensive international experience, combined with a strong track record in organizational governance, succession planning and people strategy development," said Jean-Marc Huet, Chairman of the Lonza Board. "Stephen will play an important role in helping develop and embed our performance culture. This will support our ambition to attract and retain world-leading talent and bring our high-performing teams to the next level." The board's emphasis on Fry's people strategy experience suggests Lonza is prioritizing human capital development as a competitive advantage in the contract manufacturing sector.
The nomination occurs as Lonza, which describes itself as the world's largest contract development and manufacturing organization dedicated to serving the healthcare industry, continues to expand its global operations. With approximately 20,000 employees across five continents, the company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. Fry's committee assignments indicate his expertise will be applied to both governance oversight and talent management systems, addressing two critical areas for sustainable growth in the capital-intensive CDMO industry.
For industry observers, Fry's nomination represents a strategic board composition decision that aligns with Lonza's stated ambition to enhance its organizational capabilities. As pharmaceutical companies increasingly rely on external manufacturing partners for complex therapies, CDMOs like Lonza must maintain robust governance structures and adaptive organizational cultures to meet evolving client needs. Fry's experience navigating transformation at a major pharmaceutical company could provide valuable perspective as Lonza scales its operations and refines its service offerings. Additional information about the nomination is available through the original release on NewMediaWire.
